CompletedPhase 2

Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic

Egypt126 participantsStarted 2023-12-01

Plain-language summary

Objective: To compare the efficacy, safety, and recurrence rates of topical salicylic acid/lactic acid (SA/LA) monotherapy (Group A), intralesional Candida antigen (CA) monotherapy (Group B), and their combination (Group C) for the treatment of warts.

Who can participate

Age range5 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Single or multiple warts.
✓. Aged 5 to 60 years.
✓. Eligible for both topical and intralesional treatments.
✓. No prior wart treatment for at least 1 month.

Exclusion criteria

✕. Pregnancy or lactation.
✕. Immunosuppression or use of immunosuppressive drugs.
✕. Known sensitivity to study ingredients.
✕. Systemic/local inflammation or infection.
✕. History of bleeding/clotting disorder, or use of anticoagulants/NSAIDs.
✕. History of asthma, allergic skin disorders, or convulsions.
✕. History of chronic systemic diseases (renal/hepatic failure, cardiovascular disorders).

What they're measuring

Complete Response (CR) Rate

Timeframe: 3 months post-treatment

Trial details

NCT IDNCT07329907

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Warts trials